Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
Technology appraisal guidance
Reference number: TA1037
Published:
Please note that the evaluation of pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer ID3907, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer.